Description
The MR10-2 monoclonal antibody reacts with the Vβ9 T-cell Receptor (TCR) of mice having the b haplotype (e.g., A, BALB/c, CBA/Ca, C3H/He, C57BL) of the Tcrb gene complex. The Tcrb-V9 gene locus is deleted in mice having the a (e.g., C57BR, C57L, SJL, SWR) or c (e.g., RIII) haplotype. Vβ9-bearing T lymphocytes are clonally eliminated in mice expressing superantigen encoded by Mtv-7 (Mls-1a, Mlsa) provirus (e.g., AKR, CBA/J, DBA/2), and activation or elimination of Vβ9 TCR-expressing T cells by this determinant is partially dependent upon presentation by I-E. Mtv-43 (e.g., MA/MyJ), Mtv-44 (e.g., NZW), and/or exogenous MMTV-SW superantigens also cause incomplete elimination of Vβ9 TCR-bearing T cells. Plate-bound MR10-2 antibody activates Vβ9 TCR-bearing T cells.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please observe the following precautions: Absorption of visible light can significantly alter the energy transfer occurring in any tandem fluorochrome conjugate; therefore, we recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to prevent exposure of conjugated reagents, including cells stained with those reagents, to room illumination.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
5. An isotype control should be used at the same concentration as the antibody of interest.
6. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
7. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
8. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
9. Researchers should determine the optimal concentration of this reagent for their individual applications.
